Jafarinia 2012.

Methods	A 6‐week randomised, double‐blind, parallel group study with 2 arms: Bupropion Methylphenidate
Participants	Number of participants screened: 55 Number of participants included: 44 Number of participants randomised to methylphenidate: 22 Number of participants followed up: 19 Number of withdrawals: 3 Diagnosis of ADHD: DSM‐IV‐TR (subtype: not stated) Age: mean 9.7 (1.9) years (range 6‐17) Sex: 14 males, 6 females Methylphenidate‐naïve: 100% Ethnicity: 100% Persian Comorbidity: none Comedication: not stated IQ: above 70 Sociodemographics: not stated Inclusion criteria 6‐17 years old DSM‐IV‐TR diagnostic criteria for ADHD confirmed by a child and adolescent psychiatrist Total or subscale scores (or both) of ≥ 1.5 SDs above norms for patient's age and gender on Attention‐Deficit/Hyperactivity Disorder Rating Scale‐IV (ADHD‐RS‐IV) ‐ School Version The children and their parents had to be willing to comply with all requirements of the trial Exclusion criteria Psychiatric comorbidities (excluding oppositional defiant disorder) High risk of suicide Mental retardation (IQ < 70) Clinically important chronic medical condition (such as epilepsy and organic brain disorders) Drug abuse or dependence in the last 6 months Hypertension or hypotension History of allergy to bupropion or methylphenidate Abnormal electrocardiogram Psychotropic medication use in the last 14 days
Interventions	Participants were randomly assigned to methylphenidate or bupropion Methylphenidate dosage range: 20‐30 mg/day depending on weight (20 mg/day for 30 kg and below and 30 mg/day for above 30 kg) Methylphenidate mean dosage at week 6: 25.5 mg/day Administration schedule: not stated Duration of intervention: 6 weeks Titration period: 3 weeks initiated after randomisation Treatment compliance: not stated
Outcomes	Non‐serious adverse events: Side effects measured in both groups. 11 side effects were recorded during the course of the study
Notes	Sample calculation: yes Any withdrawals due to adverse events: not stated Ethics approval: yes Funding/vested interests: public funding Key conclusions of study authors: bupropion has a comparable safety and efficacy profile with methylphenidate in children and adolescents with ADHD Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: all participants were methylphenidate‐naïve Supplemental information requested from the authors twice in August 2013 with no answer